Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cediranib - AstraZeneca

Drug Profile

Cediranib - AstraZeneca

Alternative Names: AZD-2171; Cediranib-maleate; Recentin; Zemfirza

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cancer Research UK; Institute of Cancer Research; Mario Negri Institute for Pharmacological Research; Merck Sharp & Dohme; Myriad Genetic Laboratories; National Cancer Institute (Canada); National Cancer Institute (USA); Royal Marsden NHS Foundation Trust; University College London; University Health Network; University of London; University of Manchester; University of Oxford
  • Class Antineoplastics; Ethers; Fluorinated hydrocarbons; Indoles; Pyrrolidines; Quinazolines; Small molecules
  • Mechanism of Action Platelet-derived growth factor inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II Alveolar soft part sarcoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Malignant-mesothelioma; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • No development reported Gynaecological cancer
  • Discontinued Acute myeloid leukaemia; Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Soft tissue sarcoma

Most Recent Events

  • 20 Oct 2023 Efficacy data of phase III trial in ovarian cancer was presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 01 Jul 2023 AstraZeneca completes the phase II COMICE trial in Cervical cancer (Combination therapy, Late-stage disease, Recurrent, Maintenance therapy, Second-line therapy or greater) in United Kingdom (PO) (ISRCTN10841582) (NCT04487587) (EudraCT2016-004215-13)
  • 02 Jun 2023 Pharmacodynamics data from a phase II COMICE trial in Endometrial cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top